The product identifier “Xiangge Zhili Powder Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions” describes a non-sterile bulk active pharmaceutical ingredient supplied as a powder for further pharmaceutical compounding. It is not a finished veterinary dosage form and is not administered directly without formulation, release testing, and marketing authorization. The descriptor does not identify a device model; it is a grade designation that communicates the range of downstream unit operations for which the powder may be considered. Because the powder is not sold as a sterile or depyrogenated material, injectable formulations require validated aseptic filtration through a 0.22 µm sterilizing-grade membrane or terminal sterilization where stability permits. Batch-specific certificates of analysis provide controlling values for all parameters, including those discussed below.

What specification controls apply to Xiangge Zhili Powder as a veterinary API?

Release testing is organized around identity, assay, impurities, residual solvents, water content, residue on ignition, elemental impurities, particle size distribution, bulk/tapped density, and microbial quality. The relevance of each test shifts with the intended finished route. A powder intended only for oral premix may not require the same bacterial endotoxin control as material reserved for injectable compounding. The finished-product manufacturer must assign the appropriate specification from the certificate of analysis and from the pharmacopoeial or regulatory monograph applicable to the target species and dosage form.

Particle size distribution should be measured by laser diffraction according to ISO 13320:2020. The batch-specific D10, D50, and D90 values influence content uniformity in low-dose dry blends and re-dispersibility in suspensions. Water content by Karl Fischer titration or loss on drying is limiting because excess moisture accelerates hydrolysis, agglomeration, and microbial growth. For non-sterile veterinary API powders, loss on drying is commonly controlled below 5.0% w/w, but the actual limit remains batch- and manufacturer-specific. If the powder is exposed to ambient moisture above the release limit, re-drying in a fluid-bed dryer with product temperature not exceeding 40–60 °C may be evaluated only after confirming thermal stability.

Elemental impurities should be evaluated according to ICH Q3D and, where regional rules apply, VICH GL18 or pharmacopoeial chapters such as USP <232>, USP <233>, and EP 5.20. The choice of target elements is risk-based and depends on the synthetic route, water source, equipment contact surfaces, and excipients used later. Residual solvents are controlled according to ICH Q3C or VICH GL18; if the powder is produced using an organic solvent, the certificate of analysis should list the solvent and its batch result. Absence of data for a specific solvent should not be interpreted as absence of risk.

For tablet and capsule manufacture, the powder is not a directly compressible finished blend. It must be combined with diluents, binders, disintegrants, and lubricants that are selected for the target species, tablet hardness, disintegration time, and dissolution behavior. The powder’s flow and compaction behavior are assessed by USP <616> for bulk and tapped density and by a shear cell or compressibility index determination. If the compressibility index is above 25%, direct compression is generally not robust, and wet or dry granulation is preferred.

Wet granulation may be performed in a high-shear granulator with impeller speed 100–300 rpm and chopper speed 1500–3000 rpm, followed by fluid-bed drying to a loss-on-drying endpoint in the range of 1.0–3.0% w/w for compression. The dry granules are milled through a screen of 0.8–1.6 mm. For moisture-sensitive formulations, dry granulation by roller compactor with compaction force 20–70 kN and subsequent milling can avoid aqueous binder exposure. The final lubricated blend should be compressed on a rotary tablet press equipped with precompression; ejection force, tablet hardness, friability, and disintegration should be monitored at startup and at regular intervals.

In direct compression trials, the powder and excipients should be blended in a V-blender or bin blender. A total blend time of 10–30 min is often evaluated, but longer blending can generate fines or de-mix. Lubricant should be added as a final step and blended for 3–5 min to avoid over-lubrication. Tablet hardness for veterinary oral tablets typically ranges from 40–80 N depending on tablet size and dissolution requirements; friability is assessed by USP <1216> or EP 2.9.7, with a common limit of not more than 1.0% weight loss. Disintegration time is measured by USP <701> or EP 2.9.1.

For capsule filling, tamping-pin or dosator encapsulation machines require a consistent powder bed density and acceptable flow. Weight variation is evaluated by USP <905> or EP 2.9.5. Content uniformity of the finished tablet or capsule is also assessed using pharmacopoeial procedures, and stratified sampling during the compression or encapsulation run is used to detect hopper segregation. If segregation is suspected, the powder may require a finer carrier premix or the addition of a glidant such as colloidal silicon dioxide at 0.1–0.5% w/w, followed by remixing. Dosator machines may require a minimum plug height and compression factor; tamping-pin machines require a uniform powder bed and a stable fill volume. Batch-to-batch variation in particle size can shift fill weight; therefore, encapsulation should be monitored by in-process control charts for net fill and weight variation. If the powder has a low melting point or is sensitive to heat, capsule fillers should be operated at room temperature below 25 °C where possible.

When injectable or solution dosage forms are required, further purification and sterility constraints are imposed

Injectable manufacture from this powder requires the assumption that the material is not sterile, not depyrogenated, and not particle-free. Aqueous solutions must be compounded in a controlled environment and passed through a 0.22 µm sterilizing-grade filter; the filtered solution is then either aseptically filled or terminally sterilized. If the active substance is heat-labile, aseptic processing is mandatory. If the solution is stable at elevated temperature, steam sterilization at 121 °C for 15 min may be used, provided that container closure integrity and chemical stability have been demonstrated.

If terminal sterilization is selected, validation follows a combined physical and biological approach. Steam sterilization at 121 °C for 15 min may produce an F₀ value of 15 min only when the entire solution mass reaches the target temperature; thermal mapping of the autoclave load and a biological indicator challenge with Geobacillus stearothermophilus are required. If the solution is heat-labile, aseptic filtration through a 0.22 µm filter is used, and the filter integrity is tested before and after use by bubble point, diffusion, or water intrusion method. The filtered solution should be held in a sterilized receiving vessel under grade A or equivalent conditions; hold times exceeding 24 h require validation.

Bacterial endotoxin control is required for parenteral products. The endotoxin limit must be derived from the intended species, body weight, dose volume, and route; no single universal limit applies to all veterinary injections. The incoming certificate of analysis should be checked for an endotoxin value only when the powder is designated for injectable manufacture; otherwise, the oral-grade material should not be reallocated to parenteral use without additional depyrogenation purification. Particulate matter must be controlled by light obscuration or membrane microscopy according to USP <788> or EP 2.9.19. Container closure integrity should be evaluated by USP <1207> during stability and process validation.

Solution and suspension development requires a pH-solubility profile, buffer compatibility, and vehicle selection. Published data for this specific configuration across all solvents and species-relevant formulations are limited. The formulator must screen phosphate, acetate, and citrate buffers where pH adjustment is needed, and should confirm that the active substance does not precipitate or degrade during hold times. Avoid combining the powder with strong oxidizing agents or extremes of pH unless forced-degradation data support the combination.

Sterility of the final injectable product should be assessed by membrane filtration according to USP <71> or EP 2.6.1. Filtration of viscous solutions may require pre-filtration through a larger pore size, but the final sterilizing filter must remain 0.22 µm or finer. If a suspension is developed instead of a solution, particle size in the final container should be controlled for syringeability and re-dispersibility, and the suspension should be tested for sedimentation volume, zeta potential where feasible, and injectability force.

In dry powder, granule, and medicated premix operations, the dominant process risks are segregation, inadequate deagglomeration, and non-uniform distribution. The powder should be preblended with a compatible carrier before introduction into the main mixer. Carriers such as lactose monohydrate, corn starch, or calcium carbonate may be used depending on the target species and feed stability. Mixer type, load level, and mixing time should be established by homogeneity studies; sampling from at least 10 locations after discharge is common, with active assay relative standard deviation generally below 5% for high-dose premixes and below 10% for low-dose concentrates depending on the filing standard.

Segregation tendency in bulk solids may be screened according to ASTM D6940-17 or by direct final blend uniformity data. If the powder is to be incorporated into pellets or extruded granules, the thermal and moisture history of the process should be considered; pellets made by extrusion-spheronization or pelleting may expose the API to local friction and temperature. Stability protocols should include solid-state storage at 25 °C/60% RH and 40 °C/75% RH following VICH GL3 or the applicable regional guidance.

Granulation for sachet or in-feed granules may be performed using a fluid-bed top-spray process with inlet air temperature 50–70 °C and spray rate controlled to avoid overwetting. The granule size distribution after drying may be measured by sieve analysis; a target of 90% retained between 0.25 mm and 1.0 mm is common for free-flowing granules, but the exact range depends on the dosage device or feed mixing equipment. Fines below 0.15 mm may increase dust and segregation; oversize granules may require milling.

Dust control and operator exposure are important when handling a high-activity veterinary powder. Downflow booths, local exhaust ventilation, and containment systems should be selected based on the active substance’s occupational exposure limit. Cross-contamination risks in multi-product facilities are controlled by validated cleaning procedures and by analytical verification of cleaning samples using high-performance liquid chromatography or total organic carbon. The acceptance limit for residual active is typically derived from the pharmacological or toxicological threshold and the next product’s batch size; no universal numerical limit applies.

Comparative differences from single-dosage-form veterinary API powders

The multi-dosage designation differs from a single-route API in specification breadth and processing expectations. A powder intended only for oral solids may be released with a wider particle size distribution and without endotoxin testing; a powder intended only for injectable manufacture may be sold as sterile or with a very low bioburden and tight endotoxin limit. Xiangge Zhili Powder is positioned as a non-sterile multi-dosage grade with microbial quality appropriate for oral and premix manufacture, but it requires downstream filtration or terminal sterilization for injectable use. This distinction does not make the product inferior or superior; it makes it different in operational controls.

The table above compares typical profiles. It is not a substitute for batch-specific data. If a manufacturer intends to switch from a dedicated injectable-grade API to this multi-dosage powder, the change must be justified by comparability studies covering impurity profile, particle size after reconstitution, endotoxin, and container closure compatibility. Likewise, replacement of a directly compressible tablet grade may require reformulation of the filler-binder system and lubricant level.

A multi-dosage API label is not a substitute for route-specific validation

The presence of seven listed dosage forms on the label does not demonstrate that the powder will perform identically in each form. Each finished-product manufacturer is responsible for verifying identity, strength, purity, and quality under the target marketing authorization. Published industrial data specific to Xiangge Zhili Powder across all seven dosage forms are limited; the process descriptions above represent pharmaceutical engineering frameworks rather than product-specific validation reports.

Operational boundaries follow from the material’s non-sterile powder state and likely moisture sensitivity. Storage in tightly closed containers below 25 °C and 60% RH is the standard default for similar veterinary API powders unless the certificate of analysis specifies otherwise. Batches exposed to high humidity or long ambient hold times should be re-evaluated for water content, flow, and microbial enumeration before use. Re-drying may be considered only after confirming thermal stability and absence of particle fusion; a fluid-bed dryer with product temperature not exceeding 40 °C can serve as an evaluation unit, but the cycle must be validated. Do not blend the powder with amine-based excipients, strong oxidizing agents, or highly acidic carriers without forced-degradation compatibility data. Such combinations may accelerate impurity formation or reduce active content.